Mature results of a prospective randomized trial comparing a three- weekly with an accelerated weekly schedule of cisplatin in advanced ovarian carcinoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 22, Issue 6, 1999, Pages 559-567

  Cocconi, Giorgio ^a   Bella, Mariangela ^b   Lottici, Renata ^b   Leonardi, Francesco ^b   Ceci, Guido ^b   Passalacqua, Rodolfo ^b   Di Blasio, Beatrice ^b   Bordi, Cesare ^b   Biscottini, Bruno ^b   Melpignano, Mauro ^b   De Biasi, Danilo ^b   Finardi, Cecilia ^b   Bacchi, Marisa ^b  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b NONE

Author keywords

Chemotherapy; Cisplatin; Dose intensity; Ovarian carcinoma; Survival

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OTOTOXICITY; OVARY CARCINOMA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; SURVIVAL RATE;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0033509257     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199912000-00005     Document Type: Article

References (27)

1. Ozols RF, Young RC. Chemotherapy of ovarian cancer. Semin Oncol 1991;18:222-32.
2. Levin L, Hryniuk WM. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 1987;5:756-67.
3. International Federation of Gynecology and Obstetrics (FIGO). Changes in definition of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol 1987;156:263-4.
4. Neijt JP, ten Bokkel Huinink WW, van der Burg ME, et al. Randomized trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. Lancet 1984;2:594-600.
5. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
6. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
7. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977;35:1-39.
8. SAS user's guide. Statistics, version 5 ed. Cary, NC: SAS Institute, 1985.
9. Hryniuk WM, Goodyear M. The calculation of received dose intensity. J Clin Oncol 1990;8:1935-6.
10. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Br Med J 1991;303:884-93.
11. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334:1-6.
12. Muggia FM, Braly PS, Brady MF, et al. Cisplatin or paclitaxel, versus their combination in suboptimal stage III and IV epithelial ovarian cancer. Gynecologic Oncology Group Study #132. Proc ASCO 1997;16:352a.
13. Ovarian Cancer Meta-Analysis Project. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. J Clin Oncol 1991;9:1668-74.
14. A'Hern RP, Gore ME. Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 1995;13:726-32.
15. Ngan HYS, Choo YC, Cheung M, et al. A randomized study of high-dose versus low-dose cis-platinum combined with cyclophosphamide in the treatment of advanced ovarian cancer. Chemotherapy 1989;35:221-7.
16. Kaye SB, Lewis CR, Paul J, et al. Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 1992;340:329-33.
17. Kaye SB, Paul J, Cassidy J, et al. Mature results of a randomized trial of two doses of cisplatin in the treatment of ovarian cancer. J Clin Oncol 1996;14:2113-9.
18. McGuire WP, Hoskins WJ, Brady MF, et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecology Oncology Group study. J Clin Oncol 1995;13:1589-99.
19. Conte PF, Bruzzone M, Camino F, et al. High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest. J Clin Oncol 1996;14:351-6.
20. Colombo N, Pittelli MR, Parma G, et al. Cisplatin dose intensity in advanced ovarian cancer: a randomized study of conventional dose vs dose-intense cisplatin monochemotherapy. Proc ASCO 1993; 12:255.
21. Dittrich C, Obermair A, Kurz C, et al. Prospective randomized trial of cisplatin/carboplatin vs conventional cisplatin/cyclophosphamide in epithelial ovarian cancer first results of the impact of platinum dose intensity on patient outcome. Proc ASCO 1996;15:279.
22. Ackermann S, Jager W, Merkle E, Martus P, Lang N. High-dose versus low-dose cis-platinum plus treosulfan chemotherapy in advanced epithelial ovarian cancer: results of a prospective randomized trial. Proc ASCO 1997;16:358a.
23. Gore M, Mainwaring P, A'Hern R, et al. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. J Clin Oncol 1998;16:2426-34.
24. Fennelly D. Dose intensity in advanced ovarian cancer: have we answered the question? Clin Cancer Res 1995;1:575-82.
25. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335:1950-5.
26. Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996;14:2101-12.
27. Oxols RF, Thigpen JT, Dauplat J, et al. Dose intensity. Ann Oncol 1993;4(suppl 4):S49-56.